Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $13,863 | $48,534 | $43,048 | $44,148 |
| - Cash | $3,707 | $7,474 | $9,112 | $12,959 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $10,157 | $41,060 | $33,936 | $31,190 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | $0 | -$14,578 | -$12,093 | -$12,814 |
| % Margin | – | – | – | – |
| Net Income | -$14,103 | -$14,578 | -$12,093 | -$12,748 |
| % Margin | – | – | – | – |
| EPS Diluted | -17.59 | -23.01 | -22.36 | -24.96 |
| % Growth | 23.6% | -2.9% | 10.4% | – |
| Operating Cash Flow | -$10,383 | -$9,801 | -$7,542 | -$5,014 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$10,383 | -$9,801 | -$7,542 | -$5,014 |